Play The Percentages With ARM Holdings plc

How reliable are earnings forecasts for ARM Holdings plc (LON:ARM) — and is the stock attractively priced right now?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The forward price-to-earnings (P/E) ratio — share price divided by the consensus of analysts’ forecasts for earnings per share (EPS) — is probably the single most popular valuation measure used by investors.

However, it can pay to look beyond the consensus to the spread between the most bullish and bearish EPS forecasts. The table below shows the effect of different spreads on a company with a consensus P/E of 14 (the long-term FTSE 100 average).

EPS spread Bull extreme P/E Consensus P/E Bear extreme P/E
Narrow 10% (+ and – 5%) 13.3 14.0 14.7
Average 40% (+ and – 20%) 11.7 14.0 17.5
Wide 100% (+ and – 50%) 9.3 14.0 28.0

In the case of the narrow spread, you probably wouldn’t be too unhappy if the bear analyst’s EPS forecast panned out, and you found you’d bought on a P/E of 14.7, rather than the consensus 14. But how about if the bear analyst was on the button in the case of the wide spread? Not so happy, I’d imagine!

ARM Holdings

Today, I’m analysing Footsie tech giant ARM Holdings (LSE: ARM) (NASDAQ: ARMH.US), the data for which is summarised in the table below.

Share price 926p Forecast EPS +/- consensus P/E
Consensus 24.1p n/a 38.4
Bull extreme 27.2p +13% 34.0
Bear extreme 22.5p -7% 41.2

I was quite surprised to find that, with the most bullish EPS forecast 13% higher than the consensus, and the most bearish 7% lower, ARM’s 20% spread is half as narrow as the 40% spread of the average blue-chip company.

I mean, we’re talking about a high-growth tech company, yet analysts see plausible earnings scenarios in around as narrow a spread as such defensive stalwarts as drinks group Diageo (23%) and pharma firm GlaxoSmithKline (17%).

The answer is that ARM isn’t some flighty tech small cap, whose earnings ‘could be anything’. This is a highly cash-generative £13bn company. ARM is the world’s leading semiconductor technology designer, and has a stranglehold on mobile phones, in more than 95% of which ARM’s designs are used.

The visibility afforded by ARM’s business model is also helpful for analysts’ earnings projections. Basically, operational costs can be netted off against revenues from the new technologies that ARM licences, leaving relatively predictable ongoing royalty revenues as the basis for earnings forecasts.

Just because this revenue stream is relatively predictable, though, doesn’t mean to say it isn’t growing fast. It is! As the licensing base grows, royalty revenues gather momentum: we’ve seen a more than 10-fold increase over the past 10 years.

With its dominant market position, phenomenal history of earnings growth, and new opportunities in an ever-more connected world, ARM’s shares trade on an eye-watering P/E. I have to say, the narrowness of the EPS spread doesn’t help much when we’re talking about a consensus P/E of 38.4 — and the decimal point at this level becomes pretty ridiculous!

US tech investors may not bat an eyelid at buying on such P/E, but many of us in the UK balk at the idea. I know I do. The best I can offer anyone keen on the company is that the share price is getting on for £2 lower than investors were willing to pay at the turn of the year.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »